Ionis Pharmaceuticals
E24882
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
Aliases (2)
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
→
pharmaceutical company → public company → |
| aimsTo |
treat diseases by targeting RNA
→
|
| basedIn |
California
→
|
| coDeveloped |
Spinraza
→
|
| coDevelopedWith |
Biogen
→
|
| country |
United States
→
|
| develops |
antisense oligonucleotide drugs
→
|
| focusesOn |
cardiovascular diseases
→
metabolic diseases → neurological diseases → rare diseases → |
| formerName |
Isis Pharmaceuticals
→
|
| foundedBy |
Stanley T. Crooke
→
|
| foundingYear |
1989
→
|
| hasCollaborationWith |
AstraZeneca
→
Bayer → Biogen → GSK → Novartis → Pfizer → Roche → |
| hasSubsidiaryOrAffiliate |
Akcea Therapeutics (historical affiliate)
→
|
| headquartersLocation |
Carlsbad, California, United States
→
|
| industry |
biotechnology
→
pharmaceuticals → |
| listedOn |
NASDAQ-100 Biotechnology Index
→
|
| notableProduct |
Spinraza
→
Tegsedi → Waylivra → |
| primaryBusinessModel |
drug discovery and development
→
|
| regionServed |
global
→
|
| researchArea |
cardiometabolic diseases
→
genetic diseases → neurodegenerative diseases → |
| revenueSource |
collaboration payments
→
licensing revenue → product sales → |
| specializesIn |
RNA-targeted therapeutics
→
antisense technology → |
| stockExchange |
NASDAQ
→
|
| technologyPlatform |
antisense oligonucleotide platform
→
|
| therapeuticApproach |
RNA-targeted drug discovery
→
|
| tickerSymbol |
IONS
→
|
| uses |
antisense oligonucleotides to modulate RNA
→
|
| website |
https://www.ionispharma.com
→
|
Referenced by (4)
| Subject (surface form when different) | Predicate |
|---|---|
|
Biogen
→
|
collaboratesWith |
|
Spinraza
→
|
developedBy |
|
Ionis Pharmaceuticals
("Isis Pharmaceuticals")
→
|
formerName |
|
Ionis Pharmaceuticals
("Akcea Therapeutics (historical affiliate)")
→
|
hasSubsidiaryOrAffiliate |